The purpose of this study is to find out how long a participant keeps taking guselkumab or continues with their treatment plan without stopping (treatment persistence) in participants with moderate to severe Crohn's disease (CD) or ulcerative colitis (UC) in real-world setting. CD and UC are inflammatory bowel diseases, a group of inflammatory conditions of the colon and small intestine.
Inclusion criteria:
Exclusion criteria:
Participate-In-This-Study1@its.jnj.com
Participants with confirmed diagnosis of moderate to severe crohn's disease (CD) or ulcerative colitis (UC) treated with guselkumab in accordance with routine clinical practice as per the approved prescribing label will be enrolled. No drug will be provided as a part of this study. Only data available from clinical practice and medical records will be collected within this study.
A Study of Guselkumab in Participants With Crohn's Disease and Ulcerative Colitis
A Real-World Study of Guselkumab in Ulcerative Colitis and Crohn's Disease in Saudi Arabia
A Study to Observe Real-world Evidence of Guselkumab Treatment in Participants With Ulcerative Colitis and Crohn's Disease in the United Kingdom (UK)
A Real-World Study of Guselkumab in Chinese Participants With Ulcerative Colitis
A Study of Guselkumab Treatment Persistence in Psoriatic Arthritis Participants
Efficacy and Safety of Guselkumab in Patients With Moderate-to-Severe Ulcerative Colitis:A Real-World Prospective Cohort Study.